Literature DB >> 20512788

Obesity and increased risk of cancer: does decrease of serum 25-hydroxyvitamin D level with increasing body mass index explain some of the association?

Zoya Lagunova1, Alina C Porojnicu, William B Grant, Øyvind Bruland, Johan E Moan.   

Abstract

Low levels of vitamin D and excess body weight are both factors associated with increased risk of cancer. The increased risk seems to be proportional to the increase in BMI, and to decrease in serum 25-hydroxyvitamin D (25(OH)D) level. Our earlier investigations suggest that serum 25(OH)D levels decrease with increasing BMI. Although the connection between cancer risk, BMI and vitamin D status might be arbitrary, it has not been discussed in the literature so far. In this study, we analyze data published in current meta-analysis, prospective studies, and systematic reviews on cancer-specific risk attributed to high BMI and low vitamin D status. The contribution of low 25(OH)D levels associated with high BMI to increased cancer risk was calculated for 13 vitamin-D-sensitive cancers with a focus on colorectal and breast cancer as the most frequently studied vitamin-D-sensitive cancer types. Our study suggests that a low vitamin D status may explain at least 20% of the cancer risk attributable to high BMI. The contribution of low 25(OH)D to the increased cancer risk with increasing BMI may be different for different cancer types. Thus, we find 40% for breast cancer, and 26 and 75% for colorectal cancer in men and women, respectively.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20512788     DOI: 10.1002/mnfr.200900512

Source DB:  PubMed          Journal:  Mol Nutr Food Res        ISSN: 1613-4125            Impact factor:   5.914


  18 in total

1.  Vitamin D suppresses leptin stimulation of cancer growth through microRNA.

Authors:  Ravi Kasiappan; Yuefeng Sun; Panida Lungchukiet; Waise Quarni; Xiaohong Zhang; Wenlong Bai
Journal:  Cancer Res       Date:  2014-09-24       Impact factor: 12.701

2.  Genetic variants in vitamin D metabolism-related genes and body mass index: analysis of genome-wide scan data of approximately 7000 Chinese women.

Authors:  T Dorjgochoo; J Shi; Y T Gao; J Long; R Delahanty; Y B Xiang; Q Cai; X O Shu
Journal:  Int J Obes (Lond)       Date:  2011-12-13       Impact factor: 5.095

Review 3.  Obesity as a risk factor for malignant melanoma and non-melanoma skin cancer.

Authors:  K Karimi; T H Lindgren; C A Koch; Robert T Brodell
Journal:  Rev Endocr Metab Disord       Date:  2016-09       Impact factor: 6.514

Review 4.  Nutrigenomics, vitamin D and cancer prevention.

Authors:  Cindy D Davis; John A Milner
Journal:  J Nutrigenet Nutrigenomics       Date:  2011-03-23

Review 5.  Decreasing 25-hydroxy-vitamin D levels account for portion of the effect of increasing body mass index on breast cancer mortality.

Authors:  Matthew L Morton; Cheryl L Thompson
Journal:  Mol Nutr Food Res       Date:  2012-11-26       Impact factor: 5.914

6.  [Nutrient Status of Vitamin D among Cancer Patients].

Authors:  Zhijun Li; Jing Shi; Zengliang Wang; Haisheng Chen; Yuguo Liu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2021-05-20

7.  Serum 25-hydroxyvitamin D and postmenopausal breast cancer survival: a prospective patient cohort study.

Authors:  Alina Vrieling; Rebecca Hein; Sascha Abbas; Andreas Schneeweiss; Dieter Flesch-Janys; Jenny Chang-Claude
Journal:  Breast Cancer Res       Date:  2011-07-26       Impact factor: 6.466

8.  Differences in vitamin D status may account for unexplained disparities in cancer survival rates between African and white Americans.

Authors:  William B Grant; Alan N Peiris
Journal:  Dermatoendocrinol       Date:  2012-04-01

9.  Vitamin d: are we ready to supplement for breast cancer prevention and treatment?

Authors:  Katherine D Crew
Journal:  ISRN Oncol       Date:  2013-02-26

10.  Model selection approach suggests causal association between 25-hydroxyvitamin D and colorectal cancer.

Authors:  Lina Zgaga; Felix Agakov; Evropi Theodoratou; Susan M Farrington; Albert Tenesa; Malcolm G Dunlop; Paul McKeigue; Harry Campbell
Journal:  PLoS One       Date:  2013-05-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.